Yunnan Baiyao Group Co Ltd
SZSE:000538
Relative Value
The Relative Value of one Yunnan Baiyao Group Co Ltd stock under the Base Case scenario is 69.1 CNY. Compared to the current market price of 57.25 CNY, Yunnan Baiyao Group Co Ltd is Undervalued by 17%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
Competitors Multiples
Yunnan Baiyao Group Co Ltd Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
CN |
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
102.1B CNY | 2.6 | 25 | 24.3 | 24.3 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
697.9B USD | 20.5 | 133.2 | 60.2 | 69.1 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
3.8T DKK | 16.3 | 45.2 | 33 | 36 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
357.8B USD | 4.4 | 8.8 | 11.8 | 15.5 | ||
US |
Merck & Co Inc
NYSE:MRK
|
323.8B USD | 5.3 | 140.4 | 33.4 | 53 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
186.8B GBP | 5.1 | 39.3 | 140.6 | 225.6 | ||
CH |
Novartis AG
SIX:NOVN
|
179.8B CHF | 4.2 | 13.3 | 9.7 | 16.1 | ||
CH |
Roche Holding AG
SIX:ROG
|
172.7B CHF | 2.9 | 15 | 8.6 | 10.2 | ||
US |
Pfizer Inc
NYSE:PFE
|
155.7B USD | 2.7 | 73.5 | 11 | 16.2 |